Revvity, Inc. (NYSE:RVTY) to Post Q1 2025 Earnings of $1.14 Per Share, Zacks Research Forecasts

Revvity, Inc. (NYSE:RVTY - Free Report) - Investment analysts at Zacks Research increased their Q1 2025 EPS estimates for Revvity in a research note issued to investors on Monday, August 19th. Zacks Research analyst I. Bandyopadhyay now expects that the company will post earnings per share of $1.14 for the quarter, up from their previous estimate of $1.12. The consensus estimate for Revvity's current full-year earnings is $4.75 per share. Zacks Research also issued estimates for Revvity's Q2 2025 earnings at $1.28 EPS, Q3 2025 earnings at $1.30 EPS, Q4 2025 earnings at $1.45 EPS, FY2025 earnings at $5.16 EPS and Q2 2026 earnings at $1.40 EPS.

Revvity (NYSE:RVTY - Get Free Report) last announced its quarterly earnings data on Monday, July 29th. The company reported $1.22 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.10. Revvity had a net margin of 6.26% and a return on equity of 7.34%. The company had revenue of $691.70 million during the quarter, compared to analyst estimates of $690.33 million. During the same period in the previous year, the business earned $1.21 EPS. The firm's revenue for the quarter was down 2.5% on a year-over-year basis.

A number of other brokerages have also weighed in on RVTY. Leerink Partnrs upgraded shares of Revvity to a "strong-buy" rating in a report on Monday, July 8th. Bank of America lifted their target price on shares of Revvity from $118.00 to $127.00 and gave the stock a "neutral" rating in a research report on Tuesday, July 30th. SVB Leerink began coverage on shares of Revvity in a research report on Monday, July 8th. They issued an "outperform" rating and a $125.00 target price for the company. Barclays lifted their target price on shares of Revvity from $115.00 to $125.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 30th. Finally, Jefferies Financial Group lifted their target price on shares of Revvity from $115.00 to $125.00 and gave the stock a "hold" rating in a research report on Monday, July 29th. Eight investment analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $123.81.

Revvity Stock Up 1.0 %

NYSE RVTY traded up $1.23 during mid-day trading on Wednesday, reaching $120.73. The stock had a trading volume of 460,868 shares, compared to its average volume of 862,344. Revvity has a 1 year low of $79.50 and a 1 year high of $128.15. The stock has a market cap of $14.90 billion, a PE ratio of 99.78, a price-to-earnings-growth ratio of 2.97 and a beta of 1.05. The company has a fifty day moving average price of $112.39 and a 200 day moving average price of $108.05. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.27 and a quick ratio of 1.92.

Hedge Funds Weigh In On Revvity

Hedge funds have recently added to or reduced their stakes in the company. Nomura Asset Management Co. Ltd. bought a new position in Revvity during the 4th quarter valued at about $3,593,000. BNP Paribas Financial Markets bought a new position in Revvity during the 4th quarter valued at about $12,039,000. Principal Financial Group Inc. bought a new position in Revvity during the 4th quarter valued at about $15,213,000. Russell Investments Group Ltd. bought a new position in Revvity during the 4th quarter valued at about $10,291,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Revvity during the 4th quarter valued at about $1,160,000. 86.65% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Revvity news, insider Joel S. Goldberg sold 4,000 shares of the business's stock in a transaction on Friday, June 7th. The shares were sold at an average price of $110.46, for a total value of $441,840.00. Following the sale, the insider now owns 36,900 shares in the company, valued at approximately $4,075,974. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Revvity news, insider Joel S. Goldberg sold 4,000 shares of the business's stock in a transaction on Friday, June 7th. The shares were sold at an average price of $110.46, for a total value of $441,840.00. Following the sale, the insider now owns 36,900 shares in the company, valued at approximately $4,075,974. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Joel S. Goldberg sold 3,500 shares of the company's stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $117.86, for a total transaction of $412,510.00. Following the sale, the insider now owns 33,400 shares in the company, valued at $3,936,524. The disclosure for this sale can be found here. 0.60% of the stock is currently owned by insiders.

Revvity Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, November 8th. Investors of record on Friday, October 18th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.23%. The ex-dividend date of this dividend is Friday, October 18th. Revvity's dividend payout ratio is currently 23.14%.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.